Veravas launches VeraBIND technology for ultra-sensitive assays and matrix free sample analysis
June 21, 2023
Veravas announced the launch of its VeraBIND (Biomarker Isolation and N-richment for Detection) technology.
Designed for use in clinical diagnostics and research, VeraBIND improves workflows and enables more sensitive detection of low abundance or previously hidden biomarkers. Once validated, it works with commercially available assays and can be run using any detection method, such as ELISA, chemiluminescence, and mass spectrometry.
